George Golumbeski
George is currently Senior Vice President of Business Development for Celgene Corporation, where he is responsible for the full array of business development activities (identification & evaluation of opportunities, structuring & negotiating transactions, in-licensing, M&A, out-licensing, and alliance management).
Prior to Celgene, George served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology. During his tenure at Novartis, George's group closed a significant number of collaboration agreements which bolstered the development pipeline. Earlier in his career, George held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to in-license rotigotine and lacosamide (both now approved agents).
George received a BA in Biology from the University of Virginia, a PhD in Genetics from the University of Wisconsin-Madison. He has spoken frequently at industry conferences and leading business schools on a variety of topics related to the collaborations within the biopharmaceutical industry.
